
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp's financial outlook is bolstered by the increasing rNPV to $1.6 billion, reflecting a positive adjustment to forecasts following the inclusion of their ABS-201 product. The anticipated positive interim efficacy readout from the MAD study in AGA patients, expected in the latter half of 2026, is viewed as a significant catalyst that could enhance investor interest. Additionally, strong preclinical evidence supporting ABS-201's unique mechanism of action, coupled with high demand for in-office treatments among prospective patients, contributes to a favorable sentiment surrounding the company's growth potential.
Bears say
Absci Corp faces several significant risks that could hinder its performance, including technology, clinical, regulatory, and commercial challenges that may impact future partnerships and market entry. The company's focus on treating conditions with high treatment burdens, such as androgenetic alopecia (AGA), highlights a gap in standard of care (SOC) for non-hormonal options, potentially limiting patient adoption of its offerings. Additionally, market dynamics, including competition and the potential for intellectual property issues, coupled with the risk of dilution, contribute to an overall negative outlook for Absci's stock.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares